1. Ключников С.О., Гнетнева Е.С. Убихинон (коэнзим Q10). Клинические аспекты. Лечащий врач. 2007; 7.
2. Ключников С.О., Гнетнева Е.С. Убихинон. Теория и клиническая практика. Педиатрия. Журнал им. Г.Н.Сперанского. 2008; 3.
3. Molyneux SL, Florkowski CM, Lever M et al. Biological Variation of Coenzyme Q10. Clin Chem 2005; 51 (2): 455–7.
4. Кравцова Л.А., Березницкая В.В., Школьникова М.А. Применение коэнзима Q10 (Кудесана) в клинической практике. Рос. вестн. перинатологии и педиатрии. 2006; 6.
5. Врожденные и наследственные заболевания: руководство по педиатрии. Под ред. П.В.Новикова. М., 2007; с. 542.
6. Wang SB, Weng WC, Lee NC et al. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr Neonatol 2008; 49 (4): 145–9.
7. Леонтьева И.В. Возможности применения коэнзима Q10 в лечении кардиомиопатий. Вестн. педиатрической фармакологии и нутрициологии. 2007; 4 (1).
8. Bhagavan HN, Chopra RK. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin Nutr 2005; 24 (3): 331–8.
9. Manzoli U, Rossi E, Littarru GP et al. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React 1990; 12 (3): 173–8.
10. Kocharian A, Shabanian R, Rafiei-Khorgami M et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol Young 2009; 19 (5): 501–6. [Epub 2009 Aug 25.]
11. Soongswang J, Sangtawesin C, Durongpisitkul K et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiology 2005; 26 (4): 361–6.
12. Sander S et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12 (6): 464–72.
13. Langsjoen H et al. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med 1994; 15 (Suppl.): S165–75.
14. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997; 18 (Suppl.): S145–51.
15. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999; 9 (2–4): 273–84.
16. Eaton S, Skinner R, Hale JP et al. Plasma coenzyme Q10 in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000; 302 (1–2): 1–9.
17. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–72.
18. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873–9.
19. Pinheiro R, Neto M et al. Left Ventricular Systolic Function Assessed by Echocardiography in Children and Adolescents with Osteosarcoma Treated with Doxorubicin Alone or in Combination with Dexrazoxane. Arq Bras Cardiol 2006; 87 (6): 699–706.
20. Shan K, Lincoff A, Yong J. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47–58.
21. Schwartz CL, Hobbie WL, Truesdell A et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. Y Clin Oncol 1993; 11: 1906–10.
22. van Dalen EC, Caron HN, Kremer LC. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer 2007; 43 (7): 1134–40.
23. Horino N, Kobayashi Y, Usui T. Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin. Acta Paediatr Scand 1983; 72: 549–51.
24. Iarussi D, Auricchio U, Agretto A et al. Protective effect of Coenzyme Q10 on anthracyclines cardiotoxicity: control study in childrenwith acute lymphoblastic leukemia and non-Hodgkin lymphoma. Mol Aspects Med 1994; 15 (Suppl.): s207–12.
25. Lodi R, Hart PE, Rajagopalan B et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 2001; 49 (5): 590–6.
26. Kosutic J, Zamurovic D. High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia. Pediatr Cardiology 2005; 26 (5): 727–30.
27. Hart PE et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 2005; 62 (4): 621–6.
28. Aeby A, Sznajer Y, Cave H, Rebuffat E et al. Cardiofaciocutaneous (CFC) syndrome associated with muscular coenzyme Q10 deficiency. J Inherit Metab Dis 2007; 30 (5): 827.
29. Каленикова Е.И., Городецкая Е.А., Медведев О.С. Фармакокинетика коэнзима Q10. Рус. мед. журн. 2008; 16 (5): 338–40.